Senticell

In early-stage cancer, circulating tumor DNA in plasma is often undetectable — leaving clinicians flying blind during the window when treatment matters most. Today's leading liquid biopsy platforms are fundamentally signal-constrained, requiring expensive computational workarounds that still miss too many patients. The result: delayed diagnoses, missed treatment windows, and preventable deaths.

Senticell's Signal Reservoir Platform exploits a previously underutilized biology: red blood cells naturally accumulate and preserve circulating tumor DNA, acting as a passive concentrator that plasma-based methods miss entirely. This means we detect cancer driver mutations, MRD, and pathogens at significantly lower disease burden — using standard PCR workflows, at lower cost, with no proprietary instruments required.

Seed round of $6-7M closed; clinical studies underway at UPenn with HPV-driven cancer cohort 60% enrolled and lung cancer cohort 30% enrolled. Technology is backed by 15+ years of peer-reviewed research published in Science Translational Medicine, JCI, and other top journals. Series A of $20M is currently open to fund CLIA build-out, LDT launch, and biopharma RUO partnerships.

• 
  Senticell Raises Nearly $7 Million In Oversubscribed Seed Round

  Pulse 2.0 · Sep 1, 2026

  Senticell has successfully closed an oversubscribed seed financing round, raising nearly $7 million to further develop its innovative liquid biopsy platform that utilizes red blood cells. Notable investors participated in this round, including The Venture City, Capital Factory, Scalpel Ventures, and Evoce Capital, along with several high-net-worth individuals who recognized the potential of this groundbreaking technology.

• 
  Senticell® Closes Oversubscribed Seed Round to Advance RBC-Based Liquid Biopsy Platform

  www.prnewswire.com

  /PRNewswire/ -- Senticell, Inc. ("Senticell" or the "Company"), a biotechnology company pioneering a new class of liquid biopsy built on red blood cell...